• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    9.580 +0.550 (+6.09%)
    Delayed Quote Updated: 12:58 PM EST, Nov 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 170,097
    Open 9.430
    Bid (Size) 9.560 (900)
    Ask (Size) 9.580 (500)
    Prev. Close 9.030
    Today's Range 9.360 - 9.640
    52wk Range 6.280 - 13.11
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push ↗
    Telix Pharmaceuticals (NASDAQ:TLX) outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management... 
    Via MarketBeat
    Topics Economy
    News headline image
    Telix Reports Third Quarter 2026 Financial Performance
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire

    Performance

    52-Week Range 26.9% below 52-week high
    9.580
    6.2852W Low 13.1152W High
    1 Week 0.2% below 1-week high
    8.981W Low 9.601W High

    Telix Pharmaceuticals Limited - American Depositary Shares (TLX) traded between $6.28 and $13.11 over the past 52 weeks and last traded at $9.58, 26.9% below its 52-week high. Over the past week it ranged between $8.98 and $9.60.

    Past 12 Months
    +3.5%
    -11.9%
    -6.9%
    -13.2%
    +25.7%
    -7.8%
    1W +$0.32
    1M -$1.30
    3M -$0.71
    6M -$1.46
    YTD +$1.96
    1Y -$0.81

    TLX was -7.8% over the past year, -13.2% over six months, +25.7% year to date, +3.5% in the last week.

    12 Months vs Market
    TLX
    -7.8%
    DIA
    +12.4%
    SPY
    +12.5%
    QQQ
    +9.9%
    IWM
    +15.8%

    Over the past 12 months TLX returned -7.8% versus DIA (Dow) +12.4%, SPY (S&P 500) +12.5%, QQQ (Nasdaq 100) +9.9% and IWM (Russell 2000) +15.8%.

    Volume & Liquidity 0.53× 3-mo avg
    Today 170,097 3-mo avg 321.3K
    1W
    246.0K
    1M
    350.6K
    3M
    321.3K
    6M
    243.3K
    YTD
    239.9K
    1Y
    224.0K

    TLX most recently traded 170,097 shares against a 3-month average daily volume of 321.3K.

    More News

    Read More
    News headline image
    Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
    From Telix Pharmaceuticals Limited; ITM Isotope Technologies Munich SE
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Appoints David Gill as Chair
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Pharmaceuticals H1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix to Host R&D Day in New York City on September 22, 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix H1 2026 Results: Investor Webcast Notification
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FDA Alignment to Advance ProstACT Global Phase 3 Trial
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix and United Imaging Announce Strategic Theranostics Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire

    Frequently Asked Questions

    Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
    Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
    What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
    Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
    The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
    What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
    The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 9.580
    When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
    The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 11/04/26 12:58 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.